Clinical Trial Update: Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 investigator-initiated trial of CPX-351 in untreated acute myeloid leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: COMPLETED | Results posted: 2024-02-22